Publications by authors named "Franck Morin"

Claim this Profile
D
Durvalumab in Patients With Treatment-Naive Stage IV NSCLC With an ECOG Performance Status of 2 to 3 and High PD-L1 Tumor Expression (IFCT-1802 SAVIMMUNE): A Multicenter Phase 2 Trial.
Valérie Gounant, Laurent Greillier, Céline Mascaux, François Pinquie, Delphine Carmier, Franck Morin

JTO Clin Res Rep· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MiR-193b-3p and miR-132-3p as prognostic biomarkers of survival in pleural mesothelioma patients treated with first-line bevacizumab plus pemetrexed-platinum chemotherapy in the IFCT-0701 MAPS phase 3 trial.
Guénaëlle Levallet, Christian Creveuil, Alexandre Léger-Vigot, Solenn Brosseau, Claire Danel, Franck Morin

Transl Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to letter Re "Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDS".
Elisa Gobbini, Alexandra Langlais, Pascale Missy, Sébastien Chanoine, Benjamin Besse, Franck Morin

Eur J Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDS.
Elisa Gobbini, Alexandra Langlais, Pascale Missy, Sébastien Chanoine, Benjamin Besse, Franck Morin

Eur J Cancer· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world efficacy of the dabrafenib-trametinib (D-T) combination in BRAF V600E-mutated metastatic non-small cell lung cancer (NSCLC): Results from the IFCT-2004 BLaDE cohort.
Aurélie Swalduz, Michèle Beau-Faller, David Planchard, Julien Mazieres, Sophie Bayle-Bleuez, Franck Morin

Lung Cancer· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Study design and rationale for IFCT- 2203 TAXIO: A study that aims to evaluate the effectiveness of a first-line chemotherapy regimen without etoposide, combined with durvalumab, for patients with extensive disease small cell lung cancer.
Denis Moro-Sibilot, Lionel Falchero, Camille Ardin, Ayoube Zouak, Olivier Molinier, Franck Morin

Respir Med Res· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Capmatinib efficacy for METex14 non-small cell lung cancer patients: Results of the IFCT-2104 CAPMATU study.
Marion Ferreira, Aurélie Swalduz, Laurent Greillier, Pauline du Rusquec, Hubert Curcio, Franck Morin

Lung Cancer· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term effectiveness and treatment sequences in patients with extensive stage small cell lung cancer receiving atezolizumab plus chemotherapy: Results of the IFCT-1905 CLINATEZO real-world study.
Lionel Falchero, Florian Guisier, Marie Darrason, Arnaud Boyer, Charles Dayen, Franck Morin

Lung Cancer· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
VEGFR2 and CD34 expression associated with longer survival in patients with pleural mesothelioma in the IFCT-GFPC-0701 MAPS phase 3 trial.
Guénaëlle Levallet, Fatéméh Dubois, Nicolas Elie, Christian Creveuil, Solenn Brosseau, Franck Morin

Lung Cancer· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO).
Marie Wislez, Julien Mazieres, Armelle Lavole, Gérard Zalcman, Olivier Carre, Franck Morin

J Immunother Cancer· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chest CT scan plus x-ray versus chest x-ray for the follow-up of completely resected non-small-cell lung cancer (IFCT-0302): a multicentre, open-label, randomised, phase 3 trial.
Virginie Westeel, Pascal Foucher, Arnaud Scherpereel, Jean Domas, Philippe Girard, Franck Morin

Lancet Oncol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A defect of amphiregulin release predicted longer survival independently of YAP expression in patients with pleural mesothelioma in the IFCT-0701 MAPS phase 3 trial.
Elodie Maille, Jérôme Levallet, Fatéméh Dubois, Martine Antoine, Claire Danel, Franck Morin

Int J Cancer· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort.
Simon Baldacci, Benjamin Besse, Virginie Avrillon, Bertrand Mennecier, Julien Mazieres, Franck Morin

Eur J Cancer· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non-Small-Cell Lung Cancer Harboring Mutations: Results From the IFCT-1703 R2D2 Trial.
Julien Mazieres, Claire Lafitte, Charles Ricordel, Laurent Greillier, Elodie Negre, Franck Morin

J Clin Oncol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tailoring maintenance chemotherapy upon response to induction chemotherapy as compared with pemetrexed continuation maintenance in advanced non-squamous NSCLC patients: Results of the IFCT-GFPC-1101 multicenter randomized phase III trial.
Pierre-Jean Souquet, Clarisse Audigier-Valette, Olivier Molinier, Alexis Cortot, Jacques Margery, Franck Morin

Lung Cancer· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-Line Afatinib plus Cetuximab for -Mutant Non-Small Cell Lung Cancer: Results from the Randomized Phase II IFCT-1503 ACE-Lung Study.
Alexis B Cortot, Anne Madroszyk, Etienne Giroux-Leprieur, Olivier Molinier, Elisabeth Quoix, Franck Morin

Clin Cancer Res· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of nivolumab in HIV-Infected patients with advanced non-small cell lung cancer after prior chemotherapy. The IFCT-1602 CHIVA2 phase 2 clinical trial.
Armelle Lavole, Julien Mazieres, Sophie Schneider, Solenn Brosseau, Lize Kiakouama, Franck Morin

Lung Cancer· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab.
Guillaume Herbreteau, Alexandra Langlais, Laurent Greillier, Clarisse Audigier-Valette, Lionel Uwer, Franck Morin

J Clin Med· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Switch maintenance chemotherapy versus observation after carboplatin and weekly paclitaxel doublet chemotherapy in elderly patients with advanced non-small cell lung cancer: IFCT-1201 MODEL trial.
Elisabeth Quoix, Clarisse Audigier-Valette, Armelle Lavolé, Olivier Molinier, Virginie Westeel, Franck Morin

Eur J Cancer· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France Study by Mutation Subtypes.
Anne-Marie Ruppert, Michèle Beau-Faller, Didier Debieuvre, L'Houcine Ouafik, Virginie Westeel, Franck Morin

JTO Clin Res Rep· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line carboplatin plus pemetrexed with pemetrexed maintenance in HIV-positive patients with advanced non-squamous non-small cell lung cancer: the phase II IFCT-1001 CHIVA trial.
Armelle Lavole, Laurent Greillier, Julien Mazières, Isabelle Monnet, Lize Kiakouama-Maleka, Franck Morin

Eur Respir J· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Phase II Trial Evaluating Treatment with EGFR-TKI Associated with Antiestrogen in Women with Nonsquamous Advanced-Stage NSCLC: IFCT-1003 LADIE Trial.
Julien Mazieres, Fabrice Barlesi, Isabelle Rouquette, Olivier Molinier, Benjamin Besse, Franck Morin

Clin Cancer Res· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study.
Alexis B Cortot, Clarisse Audigier-Valette, Olivier Molinier, Sylvestre Le Moulec, Fabrice Barlesi, Franck Morin

Eur J Cancer· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and Validation of a Simplified Prognostic Score in SCLC.
Elodie Negre, Amandine Coffy, Alexandra Langlais, Jean-Pierre Daures, Armelle Lavole, Franck Morin

JTO Clin Res Rep· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project.
Michèle Beau-Faller, Erwan Pencreach, Charlotte Leduc, Hélène Blons, Jean-Philippe Merlio, Franck Morin

Lung Cancer· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis